Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal...
18 KB (1,746 words) - 17:20, 1 July 2024
continue to emerge in modern medicine. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to...
167 KB (17,789 words) - 10:39, 16 July 2024
Research (2020-01-24). "New Drug Therapy Approvals 2019". FDA. "Ocrevus (ocrelizumab) Injection". www.accessdata.fda.gov. Retrieved 2021-07-01. "Search Orphan...
11 KB (842 words) - 13:15, 12 February 2024
monoclonal treatment, in managing this disease, other anti-CD20 drugs such as ocrelizumab, veltuzumab, and ofatumumab have been explored as potential treatments...
17 KB (1,941 words) - 14:31, 22 March 2024
and their approval status: CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab...
26 KB (2,953 words) - 22:19, 25 June 2024
deficiency, later discontinued in 2004 and replaced by Nutropin AQ. Ocrevus (ocrelizumab), for MS. Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for...
57 KB (5,236 words) - 09:00, 28 June 2024
in England, Wales and Northern Ireland will be offered injections of ocrelizumab, which can slow the progress of the disease. Princess Anne returns to...
274 KB (30,486 words) - 10:42, 19 July 2024
treatment for diseases such as multiple sclerosis and optic neuritis. Ocrelizumab "Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test"...
3 KB (130 words) - 01:26, 6 April 2023
Letolizumab Ligelizumab† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab...
38 KB (4,304 words) - 20:57, 1 December 2023
has led to some other anti-CD20 monoclonal antibodies being developed: ocrelizumab, humanized (90%-95% human) B cell-depleting agent. ofatumumab (HuMax-CD20)...
56 KB (5,025 words) - 07:44, 19 July 2024
Keliximab Zanolimumab CD11a Efalizumab CD18 Erlizumab CD20 Obinutuzumab Ocrelizumab Pascolizumab Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40...
7 KB (299 words) - 13:45, 27 April 2024
cancer indication due to promising phase II results. 2017: Ocrevus (ocrelizumab): The first FDA-approved therapy that treats both relapsing-remitting...
38 KB (3,369 words) - 17:52, 24 May 2024
Y chronic lymphatic leukemia Ocaratuzumab mab humanized CD20 cancer Ocrelizumab Ocrevus mab humanized CD20 Y multiple sclerosis Odesivimab mab human...
135 KB (4,054 words) - 22:35, 2 July 2024
anti-CD20 monoclonal antibody, has been approved for some indications. Ocrelizumab, ofatumumab, and "third-generation" anti-CD20 monoclonals are in development...
31 KB (2,727 words) - 21:26, 26 January 2024
Belimumab L04AG05 Vedolizumab L04AG06 Alemtuzumab L04AG07 Begelomab L04AG08 Ocrelizumab L04AG09 Emapalumab L04AG10 Inebilizumab L04AG11 Anifrolumab L04AG12 Ofatumumab...
3 KB (367 words) - 15:37, 25 January 2024
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Patients With Primary Progressive Multiple Sclerosis" at ClinicalTrials...
22 KB (2,389 words) - 06:43, 22 April 2024
ocaperidone (INN) ocfentanil (INN) ociltide (INN) ocinaplon (INN) ocrase (INN) ocrelizumab (INN) ocrilate (INN) ocriplasmin (INN) octabenzone (INN) octacaine (INN)...
7 KB (364 words) - 02:36, 1 July 2024
intravenous humanized CD20 Chronic lymphocytic leukemia 125486 Link ocrelizumab Ocrevus Genentech 3/28/2017 intravenous humanized CD20 Multiple sclerosis...
57 KB (4,072 words) - 07:13, 1 July 2024
clinical trial with a fully humanized anti-CD20 monoclonal antibody, ocrelizumab, replicated the results of the rituximab trial in relapsing remitting...
12 KB (1,157 words) - 02:32, 21 January 2024
beta-1a and beta-1b; monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab; and immunomodulators: glatiramer acetate...
131 KB (14,018 words) - 08:00, 24 June 2024
several more in development. Similarly, anti-CD20 monoclonal antibody Ocrelizumab is in trials for multiple sclerosis. CD21 CR2, a type I transmembrane...
96 KB (467 words) - 06:58, 14 October 2022
GlaxoSmithKline recurrent ovarian cancer responsive to platinum-based chemotherapy Ocrelizumab Genentech multiple sclerosis Dupilumab Regeneron Pharmaceuticals atopic...
34 KB (180 words) - 22:09, 8 April 2024
Keliximab Zanolimumab CD11a Efalizumab CD18 Erlizumab CD20 Obinutuzumab Ocrelizumab Pascolizumab Rituximab Ublituximab CD23 Gomiliximab Lumiliximab CD40...
38 KB (2,656 words) - 12:11, 30 October 2023
CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial (1635). Amit Bar-Or, Jeffrey Bennett...
21 KB (2,260 words) - 03:57, 27 May 2024
the α-subunit of IL-2 receptor on the surface of mature lymphocytes), ocrelizumab (against CD20 marker on B-cells). However, the frequent adverse effects...
8 KB (722 words) - 15:17, 22 March 2023
remissions. There is currently only one approved medication for PPMS—Ocrevus (Ocrelizumab). In 2006, DaSilva decided to document his challenges as a filmmaker...
13 KB (1,494 words) - 22:20, 19 April 2024
Letolizumab Ligelizumab† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab...
2 KB (87 words) - 01:28, 30 May 2023
monoclonal antibodies: Alemtuzumab (Lemtrada, Campath). Natalizumab (Tysabri) Ocrelizumab (Ocrevus) which is also approved for primary progressive (PPMS) Ofatumumab...
83 KB (9,414 words) - 17:06, 8 June 2024
Alemtuzumab, daclizumab and CD20 monoclonal antibodies such as rituximab, ocrelizumab and ofatumumab have all shown some benefit and are under study as potential...
68 KB (7,884 words) - 13:11, 16 July 2024